% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Betge:125509,
      author       = {J. Betge$^*$ and A. Barat and V. Murphy and T.
                      Hielscher$^*$ and N. C. Van Grieken and S. Belle and T.
                      Zhan$^*$ and N. Härtel and M. Kripp and O. Bacon and M.
                      Cordes and E. W. Kay and H. M. W. Verheul and M. Neerincx
                      and B. Hennessy and R. D. Hofheinz and T. Gaiser and B.
                      Ylstra and J. H. M. Prehn and D. Lambrechts and A. T. Byrne
                      and M. P. Ebert and N. Schulte},
      title        = {{O}utcome of {C}olorectal {C}ancer {P}atients {T}reated
                      with {C}ombination {B}evacizumab {T}herapy: {A} {P}ooled
                      {R}etrospective {A}nalysis of {T}hree {E}uropean {C}ohorts
                      from the {A}ngiopredict {I}nitiative.},
      journal      = {Digestion},
      volume       = {94},
      number       = {3},
      issn         = {1421-9867},
      address      = {Basel},
      publisher    = {Karger},
      reportid     = {DKFZ-2017-01635},
      pages        = {129 - 137},
      year         = {2016},
      abstract     = {This study is aimed at analyzing the survival rates and
                      prognostic factors of stage IV colorectal cancer patients
                      from 3 European cohorts undergoing combination chemotherapy
                      with bevacizumab.Progression free-survival (PFS) and overall
                      survival (OS) were analyzed in 172 patients using the
                      Kaplan-Meier method and uni- and multivariable Cox
                      proportional hazards regression models.The median PFS was
                      9.7 and the median OS 27.4 months. Patients treated at
                      centers in Germany (n = 97), Ireland (n = 32), and The
                      Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and
                      9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively.
                      Patients >65 years had a significantly shorter PFS (9.5 vs.
                      9.8 months) but not OS (27.4 vs. 27.5 months) than younger
                      patients. High tumor grade (G3/4) was associated with a
                      shorter PFS, T4 classification with both shorter PFS and OS.
                      Fluoropyrimidine (FP) chemotherapy backbones (doublets and
                      single) had comparable outcomes, while patients not
                      receiving FP backbones had a shorter PFS. In multivariable
                      analysis, age and non-FP backbone were associated with
                      inferior PFS, T4 classification and therapy line >2nd were
                      significantly associated with poor PFS and OS.The observed
                      survival rates confirm previous studies and demonstrate
                      reproducible benefits of combination bevacizumab regimens.
                      Classification T4, non-FP chemotherapy backbone, and age >65
                      were associated with inferior outcome.},
      keywords     = {Angiogenesis Inhibitors (NLM Chemicals) / Pyrimidines (NLM
                      Chemicals) / Bevacizumab (NLM Chemicals) /
                      5-fluoropyrimidine (NLM Chemicals)},
      cin          = {C060 / B110},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)B110-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27756074},
      doi          = {10.1159/000449412},
      url          = {https://inrepo02.dkfz.de/record/125509},
}